We create two virtual optimization objectives by emulating the log half maximal inhibitory concentration (pIC 50 ) of the inhibitors reported by Desai et al. for two additional tyrosine kinase receptors: the platelet-derived growth factor receptor, and stem cell growth factor KIT. Briefly, this will constitute a multi-objective optimization problem with the same unknown constraints as in the single objective case in which Atlas is tasked with finding a single inhibitor that has a polypharmacological effect, that is, a pharmaceutical agent that can act on multiple targets or disease pathways.